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Letters to the Editor 
Ciprofloxacin and 
Clostdiurn dificile- 
Associated Diarrhea 
To the Editor: 
We believe that the study report- 
ed by Yip et al.’ in the September 2001 
issue of Infection Control and Hospital 
Epidemiology regarding exposure to 
ciprofloxacin as a risk factor for 
Clostridium difficile-associated diar- 
rhea (CDAD) is flawed from both an 
epidemiologic and a microbiological 
perspective. 
Several issues regarding the 
research methodology and statistical 
analysis used in this study are worthy 
of comment. First, the authors 
matched controls to cases by date of 
admission, ward, age, and gender. 
They found that they could not also 
match on length of stay and had to use 
a second control group. If the authors 
intended to use logistic regression to 
analyze the results, then why did they 
match on so many factors? It would 
have been easier to match only on date 
of admission and ward, and then 
include the remaining variables in the 
analysis. This would have had the 
added advantage of exploring interac- 
tion effects (eg, between age and 
antibiotic exposure). Moreover, 
matching on date of admission in this 
study may not have been to any advan- 
tage because the study period was 
only 3 months. The local environment 
was not likely to have changed signif- 
cantly during this period, and it would 
have been acceptable to randomly 
select controls from this period. 
Finally, matching on the factors 
described in this study does not con- 
trol for comorbidities, as stated by the 
authors. 
The authors concluded that I ‘ .  . . 
patients with CDAD were at least five 
times more likely to have been 
exposed to ciprofloxacin than control 
patients. . . .” The results should have 
been interpreted as patients with 
CDAD were between 1.2 and 24.8 
times more likely to have been 
exposed to ciprofloxacin for the first 
control group, based on univariate 
analysis, and between 1.01 and 88.4 
times for the second control group, 
based on multivariate analysis. These 
wide confidence intervals (CIS), 
although statistically significant, are of 
no real practical importance. Wide CIS 
reflect unstable odds ratio (OR) esti- 
mates that generally occur when the 
sample size is too small, reducing the 
power of the study. The lower bounds 
of CIS close to 1 (ie, the null value) pro- 
vide evidence for lack of an effect. 
When viewed in conjunction with 
other studies that have explored the 
association of ciprofloxacin with 
CDAD, this study adds nothing new. 
Shah et a1.2 found a statistically signifi- 
cant association of ciprofloxacin expo- 
sure with CDAD using patients with 
diarrhea not due to C. difFcile as con- 
trols. Although they did not report the 
OR and CI, these could be calculated 
as 2.33 and 1.23 to 4.43, respectively. 
Ciprofloxacin exposure remained sig- 
nificant in their multivariate analysis, 
along with macrolides, cefuroxime, 
and lactulose. Nath et a1.3 also report- 
ed a statistically significant association - 
of ciprofloxacin in a multivariate model 
that also found clindamycin, cef- 
tazidime, and cefuroxime to be inde- 
pendently associated with CDAD, but 
the CI of 1.05 to 13.79 provides little in 
terms of practical importance. Other 
studies have reported associations 
that have not been statistically signifi- 
cant. However, all had relatively small 
sample sizes and could have lacked 
power.4s 
Regarding the microbiology, Yip 
et al.’ state, “Ciprofloxacin and other 
oral quinolones are active against 
many intestinal bacteria. . . .” This is 
true, but ciprofloxacin (unlike the 
newer fluoroquinolones) is not active 
against the anaerobic component of 
the intestinal flora and it is these bac- 
teria that comprise the “colonization 
resistance barrier.”g We previously 
demonstrated this in an in vitro model 
in which “treatment” with cipro- 
floxacin did not result in prolieration 
of C. difficile, whereas “treatment” 
with clindamycin, a known CDAD 
inciting agent, resulted in a significant 
increase in C. diflicile.lo In addition, we 
investigated prospectively 213 patients 
receiving ciprofloxacin monotherapy 
and failed to show any association 
between CDAD and ciprofloxacin.1° 
Two of the references cited by 
Yip et al. in support of their argu- 
mentl1J2 were letters to the editor in 
Lancet in 1990. However, Yip et al. 
failed to mention our letter in Lancet in 
the same year13 that provides plausible 
explanations for the observations 
made by Bates et al.” (prior 
Salmonella infection predisposing to 
C. difficile) and Cain and O’Connor12 
(prior cc-trimoxazole therapy). 
The five patients described by 
McFarland et al.,14 for whom cipro- 
floxacin was linked with CDAD, all had 
serious disease, with four of the five 
having recurrences. That in itself sug- 
gests that factors other than 
ciprofloxacin may have been operating 
in most, if not all, of these cases. 
Clinical data and our own contin- 
uing experience would suggest that 
the rate of ciprofloxacin-induced 
CDAD remains extremely low. Sir 
Charles Gairdner Hospital has been 
Australia’s largest user of ciprofloxacin 
for more than 13 years (average 
expenditure, $220,000 [Australian] per 
year), and we have not seen a case of 
ciprofloxacin-induced CDAD when 
ciprofloxacin has been used as 
monotherapy. Thus, we would argue 
that concern about CDAD following 
ciprofloxacin is not warranted. 
However, given the wider spectrum of 
activity of the newer fluoroquinolones, 
continued surveiIlance is justified. 
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The authors reply. 
We thank Thomas et al. for their 
interest in our study. We agree that 
matching only by date of admission 
and ward would have been a reason- 
able alternative approach. We disagree 
with their comments about matching 
on date of admission. Our decision to 
use date of admission was based on 
careful consideration of circumstances 
in our hospital, particularly staffing 
shortages. This variable can readily 
change during a 3-month period, is 
potentially associated with nosocomial 
transmission, and, in our setting, is not 
easily measurable-all arguments for 
matching. Randomly selecting con- 
trols, as suggested by Thomas et al., 
may have led to a loss of precision 
compared with matching on length of 
stay. Regardless, the pertinent point is 
that we obtained similar results with 
relatively large effect sizes using two 
different sets of controls. In their inter- 
pretation of confidence intervals, 
Thomas et al. ignore the fact that it is 
the point estimate of the odds ratio that 
is most likely to reflect the “truth.”The 
point estimates of the odds ratios for 
the two sets of controls, 5.5 and 6.7, 
both based on multivariable analysis, 
obviously do not represent a “lack of 
effect” as suggested by Thomas et al. 
Their discussion about sample size 
and power is misinformed; these are a 
priori concepts that should not be used 
to interpret completed studies.’ 
Thomas et al. cite epidemiologic stud- 
ies that in fact support our findings of 
an association between fluoroquine 
lone use and Clostridium difficile-asse 
ciated diarrhea.2s3 We acknowledge 
that the generalizability of such stud- 
ies may be limited. We would suggest 
that Thomas et al. exert similar cau- 
tion when making generalizations 
based on their experience in a single 
hospital. We agree that continued sur- 
veillance of fluoroquinolones and 
Clostridium difficile-associated diar- 
rhea is justified. 
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Transmissions From 
Infected Healthcare 
Providers to Patients Are 
Medical Errors 
To the Editor: 
Do no harm. This is a principle 
all medical personnel live by and 
should be referred to whenever we 
discuss interactions between patients 
and healthcare providers. In the June 
issue of Infection Control and Hospital 
Epidemiology, there were two editori- 
als,’S2 one article; and two  letter^^,^ 
regarding the transmission of hepatitis 
B virus, hepatitis C virus, and human 
immunodeficiency virus from surgical 
personnel to patients. It serves our col- 
lective interest to analyze this issue 
through the principle stated above and 
its necessary practical’ companion, 
reducing medical errors. After all, isn’t 
transmission of disease in our health- 
care institutions by definition a med- 
ical error? 
A critical component of accident 
prevention is building systems that 
prevent errors from occurring. What 
we have learned from other industries, 
such as the aviation sector, is that 
rather than focusing on the individual, 
a successful strategy requires stan- 
dardizing procedures that everyone in 
the system must follow. If an individual 
working inside the system has the 
choice of whether to follow an aspect 
of the recommended procedures, 
doesn’t this in effect mean that there is 
no system? Instead, there is individual 
compliance or noncompliance. Could 
you imagine if the same “system” 
existed in the airline industry? Would 
we accept a situation in which the pilot 
could choose whether to conduct 
inspections before takeoff? Isn’t a pilot 
with individual choice equivalent to a 
surgeon who can choose whether to 
be vaccinated or whether to be tested 
for hepatitis B virus? 
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